The Liver That Saw It First

Levan ran a small architecture practice out of a converted apartment near Vake Park, worked long hours at a desk, and had the kind of build most people would call “solid” rather than overweight — a little thicker through the middle than he’d been at thirty, but nothing that had ever prompted a comment from a physician. His annual panel had looked the same for years: LDL cholesterol a touch above optimal but never flagged as urgent, blood pressure sitting right at the edge of normal, glucose comfortably under 100 mg/dL. What actually brought him in was almost incidental — a routine abdominal ultrasound, ordered for an unrelated complaint, came back with a single line he didn’t understand: “hepatic steatosis, mild.” His primary care physician told him not to worry about it. Levan wanted a second opinion on whether that was true.

Taken one at a time, none of Levan’s numbers would stop a physician mid-appointment. Taken together, with the ultrasound finding added in, they told a different story — one this chapter exists to make visible, because the single organ most directly involved in it is also the one organ a standard annual physical almost never asks a direct question about.

The cluster nobody names until it’s five

A single underlying abnormality — resistance to insulin’s effects — quietly drives a cluster of problems different specialists tend to examine in isolation: elevated triglycerides, low HDL, high blood pressure, and glucose dysregulation, each traveling together far too often to be coincidence. Clinical medicine eventually settled on a harmonized diagnostic threshold: metabolic syndrome, diagnosed when a person meets three or more of five specific criteria — waist circumference, triglycerides, HDL, blood pressure, and fasting glucose.

Look at that list closely, and notice what’s missing entirely: the liver. Nowhere in the five official criteria does a clinician measure, or even ask about, the organ that manufactures the triglyceride-rich lipoproteins driving that pattern, clears (or fails to clear) glucose between meals, and — as it turns out — is very often the first organ in the entire cluster to show measurable damage.

Levan met exactly one of the five official criteria. By the checklist alone, he did not have metabolic syndrome. His liver told a different, earlier chapter of the same story.

The liver that saw it first

What Levan’s ultrasound had found a name for is now most often called MASLD — metabolic dysfunction-associated steatotic liver disease, the updated term for what was known for decades as NAFLD, nonalcoholic fatty liver disease. This isn’t primarily a liver disease that happens to correlate with metabolic problems. It’s increasingly understood as the liver’s own direct expression of the same insulin resistance driving everything else in this pattern — so consistently that clinical literature routinely calls it “the hepatic manifestation of metabolic syndrome.”

When cells resist insulin’s signal, the liver doesn’t just overproduce triglyceride-rich lipoproteins — a meaningful share of the fat driving that overproduction accumulates inside the liver itself first. A liver working around that accumulated fat becomes progressively less insulin-sensitive itself, which pushes the pancreas to compensate further, which raises circulating insulin further, which drives more hepatic fat storage — a self-reinforcing loop, just running through a different organ.

This is also why MASLD shows up in people who look nothing like the population most physicians associate with fatty liver disease. A meaningful share of cases occur in patients who aren’t clinically obese by any BMI threshold — “lean” or “nonobese” MASLD — and some evidence suggests it may progress faster, likely because it goes unsuspected and unscreened for longer.

Watching two decades ahead

The CARDIA study — a prospective, biracial U.S. cohort following more than three thousand participants from young adulthood across twenty-five years — measured fasting insulin and glucose repeatedly throughout that span, then assessed liver fat directly by CT scan at the twenty-five-year mark. Participants whose insulin resistance trajectories climbed higher across young adulthood and midlife — independent of what their insulin resistance measured on the day of the liver scan itself — carried substantially higher odds of having fatty liver disease at that checkpoint. The liver wasn’t just reflecting today’s insulin resistance. It was accumulating the consequences of a trajectory that had been building for decades.

Why the liver isn’t just a liver problem

Here is the fact that makes this belong in a book about cardiac reserve rather than a book about hepatology: the leading cause of death in people with MASLD is not liver disease. It’s cardiovascular disease.

A comprehensive 2021 meta-analysis pooling 36 observational studies and more than 5.8 million adults, followed for a median of 6.5 years, found that people with MASLD carried a 45% higher risk of fatal or non-fatal cardiovascular events than people without it — a hazard ratio of 1.45, holding up after adjustment for age, sex, adiposity, diabetes, and the other established cardiometabolic risk factors. The risk climbed further with more advanced liver disease, meaning the same imaging finding that looks like a footnote on a routine ultrasound report sits at the lower-risk end of a spectrum, not a false alarm to be dismissed.

Where we go from here

Levan’s ultrasound finding, alongside his borderline waist circumference and otherwise unremarkable panel, gave us a real, if early, signal — and a reason to treat his cardiovascular risk factors with more urgency than his individual numbers would have suggested in isolation, well before three of the five official metabolic syndrome boxes were checked. Waiting for the full syndrome to declare itself is waiting for a process that may already be years underway.

Levan, like every patient in this book, is a composite — built from a pattern I have seen often enough that it deserves its own chapter, not from any single identifiable person.

Notes & sources (4 of 6)

1. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome. Circulation. 2009;120(16):1640–1645.
2. VanWagner LB, Bancks MP, Ning H, et al. Twenty-five-year trajectories of insulin resistance and pancreatic β-cell response and diabetes risk in nonalcoholic fatty liver disease. Liver Int. 2018;38(11):2069–2081.
3. Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–913.
4. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999;354(9188):1435–1439.